Abstract
Neurodegeneration is characterized by severe neuronal loss leading to the cognitive and physical impairments that define various neurodegenerative diseases. Neuroinflammation is one hallmark of neurodegenerative diseases and can ultimately contribute to disease progression. Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Unfortunately, current therapeutic options lack ability to stop or effectively slow progression of these diseases and are primarily aimed at alleviating symptoms. Thus, it is crucial to discover novel treatment candidates for neurodegenerative diseases. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type-I transmembrane glycoprotein first identified in a melanoma cell line. GPNMB augments bone mineral deposition by stimulating osteoblast differentiation. Aside from its anabolic function in the bone, emerging evidence suggests that GPNMB has anti-inflammatory and reparative functions. GPNMB has also been demonstrated to be neuroprotective in an animal model of ALS, cerebral ischemia, and other disease models. Given these discoveries, GPNMB should be investigated as a potential therapeutic option for multiple neurodegenerative diseases.
Similar content being viewed by others
References
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909
Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(S1):318–324
Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 6(2):108–119
Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228
Ross CA, Margolis RL, Rosenblatt A, Ranen NG, Bêcher MW, Aylward E (1997) Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine 76(5):305–338
Roggenbuck J, Quick A, Kolb SJ (2016) Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genetics in Medicine
Brownlee WJ, Hardy TA, Fazekas F, Miller DH (2016) Diagnosis of multiple sclerosis: progress and challenges. The Lancet
Dorsey E, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386
Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80(19):1778–1783
Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296(5575):1991–1995
Kumar V, Sami N, Kashav T, Islam A, Ahmad F, Hassan MI (2016) Protein aggregation and neurodegenerative diseases: from theory to therapy. Eur J Med Chem 124:1105–1120
Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci 97(12):6763–6768
Nucifora FC, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512):2423–2428
McCampbell A, Fischbeck KH (2001) Polyglutamine and CBP: fatal attraction? Nat Med 7(5):528–531
Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1(2):120–130
Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292(5521):1552–1555
Cleveland DW (1999) From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24(3):515–520
Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M et al (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2(3):271–276
Chen WW, Zhang X, Huang WJ (2016) Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep 13(4):3391–3396
Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4(47):1–13
Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518
DiSabato D, Quan N, Godbout JP (2016) Neuroinflammation: the devil is in the details. Journal of Neurochemistry
Streit WJ, Mrak RE, Griffin WST (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 1(1):14
Cherry JD, Olschowka JA, O’Banion MK (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11(1):98
Von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J (2015) Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 7:124
Tang Y, Le W (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53(2):1181–1194
McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21(2):195–218
Griffin WST, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J Neuropathol Exp Neurol 54(2):276–281
Griffin WST, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Mrak RE (1998) Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 8(1):65–72
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Finch CE (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21(3):383–421
McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22(6):799–809
Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer’s disease. Arch Pharm Res 33(10):1539–1556
Wisniewski HM, Terry RD (1973) Reexamination of the pathogenesis of the senile plaque. Progress in Neuropathology 2:1–26
Griffin WS, Stanley LC, Ling CHEN, White L, MacLeod V, Perrot LJ et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci 86(19):7611–7615
Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R (1993) Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein. Brain Res 629(2):245–252
Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T (1994) Brain interleukin-1 beta in Alzheimer’s disease and vascular dementia. Methods Find Exp Clin Pharmacol 16(2):141–151
Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ (1993) Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-α and blood-brain barrier damage. J Neuroimmunol 43(1):15–21
Kallaur AP, Oliveira SR, Alfieri DF, Flauzino T, Lopes J, Pereira WLDCJ, Reiche EMV (2016) Cytokine profile in patients with progressive multiple sclerosis and its association with disease progression and disability. Mol Neurobiol:1–11
Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87(1):10–20
Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154(2):194–199
Ono S, Hu J, Shimizu N, Imai T, Nakagawa H (2001) Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci 187(1):27–34
Terenghi F, Allaria S, Nobile-Orazio E (2006) Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 11(1):67–71
Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci 90(21):10061–10065
Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet 384(9942):545–555
Metman LV, Pal G, Slavin K (2016) Surgical treatment of Parkinson’s disease. Curr Treat Options Neurol 18(11):49
Marsden CD, Parkes JD (1976) “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 307(7954):292–296
Godyń J, Jończyk J, Panek D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68(1):127–138
Stella F, Radanovic M, Canineu PR, de Paula VJ, Forlenza OV (2015) Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Therapeutic Advances in Drug Safety 2042098615592116
Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344(22):1688–1700
Orrell RW (2010) Motor neuron disease: systematic reviews of treatment for ALS and SMA. Br Med Bull 93(1):145–159
Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 3
Meininger V, Bensimon G, Bradley WG, Brooks BR, Douillet P, Eisen AA, Robberecht W (2004) Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 5(2):107–117
Mitchell DJ, O’Brien MR, Joshi M (2006) Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 7(2):67–71
Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardiman O (2001) Riluzole and prognosis in ALS: findings of the Irish ALS register over a five year study period (1996–2000). Amyotroph Lateral Scler Other Motor Neuron Disord 2(suppl 2):43–44
Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A (2001) The King’s database 1999–2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2(Suppl 2):43
Wingerchuk DM, Carter JL (2014) Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clinic Proceedings 89(2):225–240
Roos RA (2010) Huntington’s disease: a clinical review. Orphanet journal of rare diseases 5(1):40
Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 205(2):295–312
Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60(8):1059–1064
Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 58(6):963–967
Ton TG, Heckbert SR, Longstreth WT, Rossing MA, Kukull WA, Franklin GM, Checkoway H (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 21(7):964–969
Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67(3):494–496
Deardorff WJ, Grossberg GT (2016) Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother:1–16
Kawas CH (2006) Medications and diet protective factors for AD? Alzheimer Dis Assoc Disord 20(3 Suppl 2):S89
Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J 2012
Aisen PS (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. The Lancet Neurology 1(5):279–284
Tsai CP, Lin FC, Lee JKW, Lee CTC (2015) Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. Journal of Epidemiology 25(2):172–177
Fondell E, O’Reilly ÉJ, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ et al (2012) Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler 13(6):573–579
Popat RA, Tanner CM, Van Den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A et al (2007) Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 8(3):157–163
Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC (2006) Minocycline for short-term neuroprotection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26(4):515–521
Investigators NN-P (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31(3):141
Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology 6(12):1045–1053
Safadi F, Xu J, Smock SL, Rico MC, Owen TA, Popoff SN (2002) Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem 84(1):12–26
Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, Safadi FF (2008) Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res 314(13):2334–2351
Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM (2010) ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One 5(8):e12093
Utsunomiya K, Owaki K, Okumura Y, Momoko YANO, Takahiro OTO, Suzuki E et al (2012) An intracellular fragment of osteoactivin formed by ectodomain shedding translocated to the nucleoplasm and bound to RNA binding proteins. Biosci Biotechnol Biochem 76(12):2225–2229
Shikano S, Bonkobara M, Zukas PK, Ariizumi K (2001) Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 276(11):8125–8134
Rezania A, Healy KE (1999) Integrin subunits responsible for adhesion of human osteoblast-like cells to biomimetic peptide surfaces. J Orthop Res 17(4):615–623
Maric G, Rose AA, Annis MG, Siegel PM (2013) Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 6:839–852
Oyewumi MO, Manickavasagam D, Novak K, Wehrung D, Paulic N, Moussa FM et al (2016) Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget 7(12):13932
Frara N, Abdelmagid SM, Sondag GR, Moussa FM, Yingling VR, Owen TA, Safadi FF (2016) Transgenic expression of osteoactivin/gpnmb enhances bone formation in vivo and osteoprogenitor differentiation ex vivo. J Cell Physiol 231(1):72–83
Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW (2002) Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 30(1):81–85
Abdelmagid SM, Belcher JY, Moussa FM, Lababidi SL, Sondag GR, Novak KM et al (2014) Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro. Am J Pathol 184(3):697–713
Sondag GR, Mbimba TS, Moussa FM, Novak K, Yu B, Jaber FA et al (2016) Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling. Exp Mol Med 48(9):e257
Bateman JP, Safadi FF, Susin C, Wikesjö UME (2012) Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model. J Periodontal Res 47(2):243–247
Chung JS, Sato K, Dougherty II, Cruz PD, Ariizumi K (2007) DC-HIL is a negative regulator of T lymphocyte activation. Blood 109(10):4320–4327
Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruiter DJ, Bloemers HP (1995) nmb, a novel gene, is expressed in low metastatic human melanoma cell lines and xenografts. Int J Cancer 60(1):73–81
Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Bigner DD (2006) Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12(7):1970–1982
Bandari, P. S., Qian, J., Yehia, G., Joshi, D. D., Maloof, P. B., Potian, J., & Rameshwar, P. (2003). Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regul Pept, 111(1), 169–178.
Huang JJ, Ma WJ, Yokoyama S (2012) Expression and immunolocalization of GPNMB, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats. Brain and behavior 2(2):85–96
Murata K, Yoshino Y, Tsuruma K, Moriguchi S, Oyagi A, Tanaka H et al (2015) The extracellular fragment of GPNMB (glycoprotein nonmelanosoma protein B, osteoactivin) improves memory and increases hippocampal GluA1 levels in mice. J Neurochem 132(5):583–594
Ono Y, Tsuruma K, Takata M, Shimazawa M, Hara H (2016) Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na+/K+-ATPase. Sci Rep 6
Moussa FM, Hisijara IA, Sondag GR, Scott EM, Frara N, Abdelmagid SM, Safadi FF (2014) Osteoactivin promotes osteoblast adhesion through HSPG and αvβ1 integrin. J Cell Biochem 115(7):1243–1253
Miyazaki T, Miyauchi S, Anada T, Tawada A, Suzuki O (2015) Chondroitin sulfate-E binds to both Osteoactivin and integrin αVβ3 and inhibits osteoclast differentiation. J Cell Biochem 116(10):2247–2257
Hu X, Zhang P, Xu Z, Chen H, Xie X (2013) GPNMB enhances bone regeneration by promoting angiogenesis and osteogenesis: potential role for tissue engineering bone. J Cell Biochem 114(12):2729–2737
Silva JV, Yoon S, Domingues S, Guimarães S, Goltsev AV, da Cruz E Silva EF et al (2015) Amyloid precursor protein interaction network in human testis: sentinel proteins for male reproduction. BMC Bioinformatics 16(1):12
Bhaskaran M, Xi D, Wang Y, Huang C, Narasaraju T, Shu W et al (2012) Identification of microRNAs changed in the neonatal lungs in response to hyperoxia exposure. Physiol Genomics 44(20):970–980
Mühlstedt S, Qadri F, Schulz H, Özcelik C, Bader M (2012) 770 a screening for novel factors in the pathophysiology of myocardial infarction reveals Osteoactivin/GPNMB. J Hypertens 30:e222
Maric G, Annis MG, Dong Z, Rose AAN, Ng S, Perkins D et al (2015) GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis. Oncogene 34(43):5494–5504
Rho HW, Lee BC, Choi ES, Choi IJ, Lee YS, Goh SH (2010) Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR. BMC Cancer 10(1):240
Nagahara Y, Shimazawa M, Tanaka H, Ono Y, Noda Y, Ohuchi K, Hara H (2015) Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neurosci Res 93(10):1552–1566
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Deng HX (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166):1772–1775
Nagahara Y, Shimazawa M, Ohuchi K, Ito J, Takahashi H, Tsuruma K et al (2016) GPNMB ameliorates mutant TDP-43-induced motor neuron cell death. Journal of Neuroscience Research
Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH (2015) Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease. PLoS One 10(3):e0120194
Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M et al (2016) Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS Open Bio 6(9):902–913
Nakano Y, Suzuki Y, Takagi T, Kitashoji A, Ono Y, Tsuruma K, Hara H (2014) Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia–reperfusion injury. Neuroscience 277:123–131
Ailane S, Long P, Jenner P, Rose S (2013) Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. Eur J Neurosci 38(3):2468–2476
Kurkowska-Jastrzębska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156(1):50–61
Schöler J, Ferralli J, Thiry S, Chiquet-Ehrismann R (2015) The intracellular domain of teneurin-1 induces the activity of microphthalmia-associated transcription factor (MITF) by binding to transcriptional repressor HINT1. J Biol Chem 290(13):8154–8165
Pahl MV, Vaziri ND, Yuan J, Adler SG (2010) Upregulation of monocyte/macrophage HGFIN (GPNMB/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 5(1):56–61
Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA (2007) GPNMB is induced in macrophages by IFN-γ and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178(10):6557–6566
Wu B, Sondag G, Malcuit C, Kim MH, Safadi FF (2015) Macrophage-associated Osteoactivin/GPNMB mediates mesenchymal stem cell survival, proliferation, and migration via a CD44-dependent mechanism. Journal of Cellular Biochemistry
Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, Bonventre JV et al (2010) The melanoma-associated transmembrane glycoprotein GPNMB controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J 24(12):4767–4781
Patel-Chamberlin M, Wang Y, Satirapoj B, Phillips LM, Nast CC, Dai T et al (2011) Hematopoietic growth factor inducible neurokinin-1 (GPNMB/Osteoactivin) is a biomarker of progressive renal injury across species. Kidney Int 79(10):1138–1148
Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14
Rowinska-Zyrek M, Salerno M, Kozlowski H (2015) Neurodegenerative diseases–understanding their molecular bases and progress in the development of potential treatments. Coord Chem Rev 284:298–312
Ripoll VM, Meadows NA, Raggatt LJ, Chang MK, Pettit AR, Cassady AI, Hume DA (2008) Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene 413(1):32–41
Loftus SK, Antonellis A, Matera I, Renaud G, Baxter LL, Reid D et al (2009) GPNMB is a melanoblast-expressed, MITF-dependent gene. Pigment Cell & Melanoma Research 22(1):99–110
Gutknecht M, Geiger J, Joas S, Dörfel D, Salih HR, Müller MR et al (2015) The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Communication and Signaling 13(1):19
Bhattacharyya S, Feferman L, Tobacman JK (2016) Inhibition of phosphatase activity follows decline in sulfatase activity and leads to transcriptional effects through sustained phosphorylation of transcription factor MITF. PLoS One 11(4):e0153463
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006) Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459–466
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69–73
Guarnieri D, Falanga A, Muscetti O, Tarallo R, Fusco S, Galdiero M, Netti PA (2013) Shuttle-mediated nanoparticle delivery to the blood–brain barrier. Small 9(6):853–862
Kabanov AV, Gendelman HE (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 32(8):1054–1082
GÜLTEKİN HE, DEĞİM Z (2013) Biodegradable polymeric nanoparticles are effective systems for controlled drug delivery. FABAD J Pharm Sci 38(2):107–118
Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P et al (2013) Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano 8(1):76–103
Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L et al (2011) Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release 151(2):131–138
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286
Spuch C, Navarro C (2011) Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). Journal of Drug Delivery
Di Stefano A, Sozio P, Iannitelli A, Marianecci C, Santucci E, Carafa M (2006) Maleic-and fumaric-diamides of (O,O-diacetyl)-l-dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target 14(9):652–661
Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A et al (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson’s disease. Proc Natl Acad Sci 98(19):10918–10923
Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH et al (2016) Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry 6(10):e907
Ren X, Zhang T, Gong X, Hu G, Ding W, Wang X (2013) AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Exp Neurol 248:148–156
Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A et al (2009) Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson’s disease rat model. The Journal of Gene Medicine 11(10):899–912
Acknowledgments
The writing of this review was supported in part by grants from the NIH (RO1ES021800) and the Michael J Fox Foundation for Parkinson’s Disease Research to JRR. Additional support was provided through generous donations from the Glenn and Karen Leppo, the Richard Nicely, and the Allan and Janice Woll Parkinson’s Research Funds. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of NIH or any other funding source.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Budge, K.M., Neal, M.L., Richardson, J.R. et al. Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease. Mol Neurobiol 55, 5167–5176 (2018). https://doi.org/10.1007/s12035-017-0707-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-017-0707-z